Academy of Managed Care Pharmacy Named AAM’s 2022 Champion of Access

WASHINGTON D.C. (February 15, 2022) – Today, the Association for Accessible Medicines (AAM) announced the Academy of Managed Care Pharmacy (AMCP) as the winner of its 2022 Champions of Access award. AAM CEO Dan Leonard presented the award at Access! 2022, the association's annual meeting.

Founded in 1988, the national professional association of pharmacists and other health care practitioners passionately and tirelessly advocates to advance the mission of improving patient health by ensuring access to high-quality, cost-effective medications and other therapies.

In particular, AMCP’s Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) is critical in bringing stakeholders together to provide unbiased scientific information on the effectiveness and safety of marketed biologics, including biosimilars.

Susan Cantrell, MHL, RPh, CAE, CEO of AMCP, said, Access is central to all we do to help patients get the medications they need at a cost they can afford. The COVID-19 pandemic has, more than ever, exposed the stark reality of cracks, inequalities and barriers in our health care system. AMCP proudly works to optimize access and address health disparities. On behalf of AMCP, I am honored to accept the Champions of Access award.

Dan Leonard, President and CEO of AAM, said, I am very pleased to present this award to the Academy of Managed Care Pharmacy on behalf of AAM, its members and the patients that we all serve. We are very grateful to AMCP for its mission of improving patient health by ensuring access to high-quality, cost-effective medications at a cost they can afford and I am proud to present them with the 2022 Champion of Access Award.

The annual Champions of Access award acknowledges individuals and organizations who share AAM’s commitment to greater access to affordable, lifesaving and health-sustaining medicines. We honor those who are dedicated to ensuring that every patient can receive the medicine he or she needs at a cost the system can bear.


Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.